Zimbabwe has rejected a major American healthcare agreement worth $367m (272 million pounds) over five years due to Washington's request for confidential biological samples.
This rejection came to light following a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government representative later explained that the US was seeking genetic material for scientific study and commercial purposes but refused to share the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued talks to reach a agreement suitable to both sides so the country's critical HIV programme can continue.
Wider Implications
This rejection follows a comparable situation in Kenya, where a court suspended a related deal with the US following legal challenges were filed about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
Based on statements, Sixteen African countries have so far signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," he stated.
"Effectively, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our people should a new disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining frameworks already established through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage continued dialogue with our US partners on how future co-operation might be arranged in a way that respects the independence and dignity of each country."
Health Experts Response
A leading public health body said it understood the official position, but urged that negotiations need to persist since much of the nation's HIV programmes relied on external financing.
"In cases where specific concerns arise, including those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it added.
The halted deal emphasises the continuing debate between receiving crucial foreign assistance and safeguarding local interests in an increasingly interconnected world.